Aridis Pharmaceuticals LLC's Also see "Aridis Pharmaceuticals LLC " - Scrip, 1 May, 2008. lead preclinical candidate is Panaecin, which is a reformulation of a commercial product containing gallium that is used to treat hypercalcemia in cancer patients. Since gallium also has anti-infective properties, Aridis plans to develop it as an inhaled powder, initially targeting cystic fibrosis patients.
BioMarck Pharmaceuticals Ltd. Also see "BioMarck Pharmaceuticals Ltd. " - Scrip, 1 May, 2008. is developing an inhaled...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?